Skip to main content

Table 3 Outcome variables in dogs on two different enzyme treatments for canine exocrine pancreatic insufficiency

From: A blinded randomised controlled trial to determine the effect of enteric coating on enzyme treatment for canine exocrine pancreatic insufficiency

Criterion Treatment group P value
Test (coated) Control (uncoated) Time Time-group
Body weight (kg)
Before 21 ±8.8 (4 to 36) 26 ±10.3 (6 to 48) --- 0.159
14 days 23 ±9.3 (5 to 40) 26 ±10.1 (7 to 48) 0.962 0.012
28 days 24 ±9.6 (5 to 39) 27 ±10.6 (8 to 48) 0.145 0.004
56 days 25 ±10.0 (6 to 39) 28 ± 10.6 (8 to 48) <0.001 <0.001
Body condition score1
Before 2 (1 to 5) 2 (1 to 6) --- 0.233
14 days 3 (1 to 5) 2 (1 to 6) 0.018 0.800
28 days 3 (1 to 5) 2 (1 to 6) <0.001 0.593
56 days 4 (2 to 5) 3 (1 to 6) <0.001 0.032
Dose of enzyme2
Before 2 (1 to 2) 2 (1 to 4) --- 0.669
14 days 2 (1 to 4) 2 (1 to 7) 0.075 0.311
28 days 2 (1 to 4) 2 (1 to 7) 0.002 0.722
56 days 2 (1 to 4) 4 (1 to 6) <0.001 0.225
Clinical score3
Before 11 (4 to 19) 13 (2 to 16) --- 0.993
14 days 8 (2 to 12) 7 (2 to 15) 0.003 0.337
28 days 7 (1 to 13) 5 (0 to 11) 0.008 0.476
56 days 7 (1 to 13) 5 (0 to 11) 0.011 0.869
Other therapy
Before Oxytetracycline (1) Cimetidine (1) --- ---
14 days Oxytetracycline (2) Oxytetracycline (1) --- ---
28 days Oxytetracycline (2) Cimetidine (1) Metronidazole (1) Oxytetracycline (2) --- ---
56 days Oxytetracycline (1) Oxytetracycline (3) Ranitidine (1) --- ---
  1. Dogs, with exocrine pancreatic insufficiency, were randomised to receive one of two enzyme treatments (test [e.g. coated] and control [e.g. uncoated]). Numerical data are expressed as median (range), except for body weight, which is expressed as mean ± standard deviation (range). 1Body condition score assessed using the 9-point system [5]. 2 Dose of enzyme in number of capsules per day. 3Clinical score was a composite score for a range of clinical signs, as described in Table 3. Body weight increased progressively in dogs on both treatments (P<0.001), but a significant time-group interaction was evident with the magnitude of increase being greater for the test treatment (coated enzyme) than for the control treatment (uncoated enzyme; P<0.001). BCS increased over time in both groups (P<0.001), but increased more in the test treatment group (P=0.032 at 56 days). The dose of enzyme used increased (P<0.001 at 56 days) and whilst clinical disease severity score decreased (P=0.011 at 56 days) over time, but with no significant treatment group differences noted.